Clinical Trial Detail

NCT ID NCT02936102
Title A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Novartis Pharmaceuticals
Indications

Advanced Solid Tumor

alveolar soft part sarcoma

triple-receptor negative breast cancer

Therapies

FAZ053

FAZ053 + Spartalizumab

Age Groups: adult senior

No variant requirements are available.